title: Mesterolone treatment of aging male syndrome improves lower urinary tract symptoms.
abstract: OBJECTIVE
  To investigate the effects of mesterolone on prostate in patients treated for aging male syndrome.
  
  
  METHODS
  The cross-sectional study was conducted from June to September, 2009, at endocrinology and metabolism department of Yuzuncu Yil University, Van, Turkey, andcomprised patients with symptoms of aging male syndrome and/or low testosterone. They were given mesterolone 50 mg/day per oral for two months. Aging Male Symptoms and International Prostate Symptom Score questionaires and prostate-related quality of life scores were completed and prostate ultrasonography (USG) was performed before and after the treatment. Total testosterone, free testosterone, gonadotropins, estradiol, prolactin, sex-hormone binding globulin, as well as total and free prostate-specific antigen were also studied.
  
  
  RESULTS
  Of the 34 patients in the study, 22(64.70%) had their prostate volume increased, while 12(35.29%) had it decreased. The change, however, was not statistically significant (p<0.098). Mesterolone significantly improved Aging Male Symptoms, International Prostate Symptom and prostate-related quality of life scores (p<0.001). These improvements though significant were independent of the changes in prostate volume. Total testosterone, sex-hormone binding globulin andestradiol decreased, while free testosterone showed no change (p<0.002, p<0.001, p<0.024, p<0.337). The fraction of free testosterone increased (p<0.001), while total and free prostate-specific antigen did not change (p<0.368 and p<0.841) CONCLUSION: Mesterolone proved to be a safe alternative in the treatment of Aging Male Syndrome. It also improved lower urinary tract symptoms and prostate-related quality of life.
authors.forename: Harun
authors.initials: H
authors.lastname: Dugeroglu
authors.forename: Mustafa
authors.initials: M
authors.lastname: Ozturk
authors.forename: Murat
authors.initials: M
authors.lastname: Atmaca
authors.forename: Ismet
authors.initials: I
authors.lastname: Seven
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000375:Aging / Q000502:physiology; D045930:Anabolic Agents / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D006801:Humans; D059411:Lower Urinary Tract Symptoms / Q000188:drug therapy*; D008297:Male; D008655:Mesterolone / Q000627:therapeutic use*; D008875:Middle Aged; D009929:Organ Size; D011467:Prostate / Q000033:anatomy & histology / Q000187:drug effects; D011788:Quality of Life; D013577:Syndrome; D055815:Young Adult
chemical_list: D045930:Anabolic Agents; D008655:Mesterolone